Metabolic disorders in heart failure and cancer. (20th December 2018)

• Record Type: Journal Article
• Authors: Lena, Alessia; Coats, Andrew J.S.; Anker, Markus S.
• Is Part Of: ESC heart failure. Volume 5:Number 6(2018)
• Page Start: 1092
• Page End: 1098
• Publication Date: 2018-12-20
• Subjects: Cachexia -- Sarcopenia -- Heart failure -- Cancer; Heart failure -- Periodicals; 616.129005
• DOI: 10.1002/ehf2.12389
• Languages: English
• ISSNs: 2055-5822

Abstract

Abstract: In an aging population, the number of patients affected by heart failure and cancer is constantly increasing and together these two conditions account for more than 50% of all deaths worldwide. Both diseases share similar risk factors including smoking, obesity, and hypertension. Presenting symptoms may also be similar, with patients frequently complaining of dyspnea, fatigue, and anorexia. Many affected patients, especially those with more advanced heart failure or cancer, suffer also from metabolic disorders. These can lead eventually to muscle wasting, sarcopenia, and cachexia. These complications are associated with increased morbidity, a poorer quality of life, a worse prognosis and indeed they represent an independent risk factor for the advancement of the underlying disease itself. Very few therapeutic options have been established to treat these co‐morbidities. For sarcopenia the only validated treatment is resistance training. Moreover, there is currently no guideline recommended therapy for the treatment of cachexia. New treatment strategies are urgently needed to prevent and treat muscle and wasting disorders in patients with chronic diseases such as cancer and chronic heart failure.